Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Netherton Syndrome treatment
market3 mentionslast seen Oct 20, 2026
Treatment of a rare skin disease.
Relationships 1
Relationship
QRX003applies toNetherton Syndrome treatment
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGAROct 20, 2026Quoin Pharmaceuticals Ltd. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
QRX003 is an investigational topical serine protease inhibitor lotion in late-stage development for Netherton Syndrome
- filingSEC EDGAROct 14, 2026Quoin Pharmaceuticals Ltd. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
QRX003 is also currently being evaluated in late-stage clinical trials for Netherton Syndrome
- filingSEC EDGARSep 22, 2026Quoin Pharmaceuticals Ltd. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The FDA granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome